4564.T Stock Down 4.2% in Pre-Market Trading on May 5

OncoTherapy Science, Inc. (4564.T) is trading lower in pre-market action on the JPX, with shares down 4.2% to ¥23.0 as of May 5, 2026. The biotech company saw trading volume surge to 179.1 million shares, more than double its average daily volume of 88.6 million. This elevated activity signals investor attention ahead of the company’s earnings announcement scheduled for May 11. 4564.T stock has faced headwinds recently, declining 8.0% over the past five days, though it remains up 9.5% year-to-date. The Kawasaki-based cancer drug developer continues advancing its clinical pipeline despite current market weakness.

Pre-Market Trading Activity and Volume Surge

4564.T stock opened at ¥23.0 with a day range between ¥23.0 and ¥25.0, reflecting modest intraday volatility. Trading volume exploded to 179.1 million shares, representing a relative volume of 2.02x normal levels. This spike suggests institutional and retail traders are positioning ahead of earnings.

The stock’s 50-day moving average sits at ¥23.04, nearly identical to current price levels. However, the 200-day moving average of ¥23.90 shows the stock trading slightly below its longer-term trend. Market sentiment appears cautious, with the stock down from its 52-week high of ¥35.0 but above its 52-week low of ¥19.0.

Financial Metrics and Valuation Concerns

OncoTherapy Science reports a market cap of ¥7.9 billion with 343.6 million shares outstanding. The company carries a negative earnings per share of -¥2.83, resulting in a negative price-to-earnings ratio of -8.13. This reflects ongoing losses as the biotech invests heavily in drug development.

The price-to-sales ratio stands at 10.08x, indicating investors are pricing in significant future growth potential. The price-to-book ratio of 3.88x suggests the stock trades at a premium to tangible assets. With a current ratio of 8.51x, the company maintains strong liquidity to fund its research programs. Track 4564.T on Meyka for real-time updates on financial developments.

Clinical Pipeline and Research Focus

OncoTherapy Science’s pipeline includes multiple cancer therapies in various clinical stages. OTS167, a maternal embryonic leucine zipper kinase inhibitor, is in Phase I/II trials for acute myeloid leukemia and Phase I trials for breast cancer. OTS964, targeting T-LAK cell-originated protein kinase, addresses various cancer diseases.

The company also develops cancer-specific peptide vaccines. S-588410 is in Phase III trials for esophageal cancer and Phase II for bladder cancer. S-488210 progresses through Phase I/II for head and neck cancer. Additionally, OncoTherapy is developing antibody drugs including OTSA101 for synovial sarcoma and KHK6640 for Alzheimer’s disease research.

Market Sentiment and Technical Indicators

Technical analysis reveals mixed signals for 4564.T stock. The relative strength index (RSI) at 44.94 suggests the stock is approaching oversold territory but hasn’t reached it yet. The MACD histogram shows negative momentum at -0.54, with the signal line above the MACD line, indicating bearish pressure.

The Stochastic oscillator (%K: 13.89, %D: 14.90) signals extreme weakness, while Williams %R at -91.67 confirms oversold conditions. The ADX at 39.65 indicates a strong downtrend is in place. Bollinger Bands show the stock trading near the lower band at ¥21.58, suggesting potential support. Money Flow Index at 53.91 remains neutral, reflecting balanced buying and selling pressure.

Final Thoughts

OncoTherapy Science (4564.T) faces near-term headwinds with pre-market weakness and elevated trading volume signaling uncertainty ahead of May 11 earnings. The biotech’s strong cash position and advancing clinical pipeline provide long-term potential, but negative profitability metrics and technical weakness warrant caution. Investors should monitor earnings results closely, as they may clarify the company’s funding runway and development timelines. The stock’s valuation remains elevated relative to current financial performance, making execution on clinical trials critical for future shareholder returns. Healthcare sector dynamics and competitive pressures in oncology also merit consider…

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.